Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Deferred Taxes (2016 - 2025)

Pediatrix Medical (MD) has disclosed Deferred Taxes for 17 consecutive years, with $24.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes rose 78.52% to $24.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $52.2 million, a 2550.05% increase, with the full-year FY2025 number at $52.2 million, up 2550.05% from a year prior.
  • Deferred Taxes was $24.5 million for Q4 2025 at Pediatrix Medical, up from $11.1 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $24.5 million in Q4 2025 to a low of -$25.7 million in Q2 2024.
  • A 5-year average of -$35750.0 and a median of $1.3 million in 2023 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: crashed 1242.46% in 2022, then surged 541.11% in 2025.
  • Pediatrix Medical's Deferred Taxes stood at -$1.0 million in 2021, then plummeted by 1242.46% to -$14.1 million in 2022, then soared by 47.76% to -$7.4 million in 2023, then soared by 287.07% to $13.8 million in 2024, then skyrocketed by 78.52% to $24.5 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Deferred Taxes are $24.5 million (Q4 2025), $11.1 million (Q3 2025), and $12.1 million (Q2 2025).